Scientists investigate why some thyroid cancers resist radioactive iodine
NCT ID NCT07314255
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines why some papillary thyroid cancers respond well to radioactive iodine-131 therapy while others do not. Researchers will compare tissue samples and PET scans from 60 patients who have already had treatment, focusing on a protein called Trop2. The goal is to understand factors that influence treatment resistance and survival, which may help guide future therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2025
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
patients who had undergone total thyroidectomy with postoperative pathology confirming papillary thyroid carcinoma and at least one radioactive iodine-131 (\^131I) therapy in the Department of Nuclear Medicine at Jiangxi Cancer Hospital over the past 8-10 years were retrospectively collected
- Ages
-
18 to 75 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria:( 1) History of total thyroidectomy with postoperative pathology confirming papillary thyroid carcinoma (PTC); (2) At least one course of \^131I internal radiotherapy. Exclusion Criteria:(1) Presence of other severe comorbidities; (2) Incomplete clinical or follow-up data.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for I-131 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, 330000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.